The recent report of the birth of the first transgenic primate, ANDi, marks an important next stage in the progressive development of novel gene therapy strategies for understanding and treating human genetic disease. The opportunities and benefits offered by this technology are significant but must be carefully balanced against the particular practical, ethical and financial costs involving the use of primates in experimental medicine.